Immune Cell Score as a Predictor of Adjuvant Chemotherapy Effectiveness in Stage II Colorectal Cancer
ICS is a strong prognostic biomarker in stage II CRC and may help refine ACT decision-making, particularly in stage IIB-C disease. Integrating ICS into clinical workflows could enable personalized adjuvant therapy by directing ACT to patients most likely to benefit.
Authors
- Matthias Kloor
- Prof Niels Halama
- Durgesh Wankhede
- Michael Hoffmeister
- Dominic Edelmann
- Hermann Brenner
Institutions
- German Cancer Research Center (DE)
- Johannes Gutenberg University Mainz (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- National Center for Tumor Diseases (DE)
- Helmholtz Institute Mainz (DE)
Publication Details
- Journal
- Journal of the National Comprehensive Cancer Network
- Published
- 2026-02-26
- DOI
- https://doi.org/10.6004/jnccn.2025.7112
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00